ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Vizgen to Present Spatial Multi-Omics Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Vizgen, Inc., a spatial multi-omics innovator accelerating biological discovery and new drug development, today announced that it will present new spatial multi-omics data at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting on November 7-10, 2025 in National Harbor, Maryland. The company will showcase how researchers can generate a combination of high-quality RNA and protein data via Vizgen’s bioinformatics technology.

Vizgen combined results from MERFISH 2.0™ gene expression data generated on the MERSCOPE Ultra™ with data collected from InSituPlex® (ISP) multiplex immunofluorescence (mIF) in sequential sections to decode the complexity of the tumor-immune microenvironment (TiME). In its session on November 7th at SITC, Vizgen will delve into how to co-register two established high-quality datasets to fuel multi-omic research.

“Vizgen is empowering researchers to use the power of spatial multi-omics to gain valuable new insights, and we’re excited to share the latest data at SITC to demonstrate what is possible to significantly advance research,” said Jiang He, VP & Portfolio Owner, Reagents & Sci. Affairs, at Vizgen. “The scientific community in attendance at SITC 2025 will get a first look at data that improves the understanding of the tumor-immune microenvironment through a unified approach with spatial multi-omics. Vizgen offers a complete solution to study the tumor microenvironment.”

POSTERS

Details of the posters at the Gaylord National Resort and Convention Center at SITC 2025 are as follows:

Abstract Number: 101

Title: Combining Vizgen’s MERSCOPE gene expression profiling and InSituPlex multiplex immunofluorescence (mIF) to reveal functional compartmentalization within the tumor microenvironment (TME)

Session Date: Friday, November 7, 2025

Session Time: Between 12:15 p.m. and 1:45 p.m. ET (Lunch session) and between 5:35 p.m. and 7 p.m. (PM reception)

Presenter: Angela Vasaturo, Director of Scientific Affairs at Vizgen

Abstract Number: 102

Title: New developments in spatial transcriptomics using MERFISH 2.0 unlock insights into the tumor microenvironment

Session Date: Saturday, November 8, 2025

Session Time: Between 12:15 p.m. and 1:45 p.m. ET (Lunch session) and between 5:35 p.m. and 7 p.m. (PM reception)

Presenter: Amanda Burke, PhD, Field Application Scientist, Vizgen

Abstract Number: 84

Title: Enabling scalable tumor microenvironment (TME) profiling with 8-plex InSituPlex multiplex immunofluorescence (mIF) on ZEISS Axioscan 7 spatial biology

Session Date: Saturday, November 8, 2025

Session Time: Between 12:15 p.m. and 1:45 p.m. ET (Lunch session) and between 5:10 p.m. and 6:35 p.m. (PM reception)

Presenter: Kevin Hwang, Ph.D., Senior Scientist, Research at Vizgen

Abstract Number: 88

Title: Establishing a robust and reproducible automated mIF workflow for spatial biology using ZEISS SlideStream and Ultivue by Vizgen’s InSituPlex assays

Session Date: Saturday, November 8, 2025

Session Time: Between 12:15 p.m. and 1:45 p.m. ET (Lunch session) and between 5:35 p.m. and 7 p.m. (PM reception)

Presenter: Cassandra Kysilovsky, Ph.D., Associate Scientist at Vizgen

In exhibit hall booth #838, Vizgen representatives will be showcasing a spatial multi-omic workflow that combines spatial transcriptomics, spatial proteomics, and AI-enhanced data science.

Abstracts

To view abstracts, visit: https://www.sitcancer.org/2025/abstracts/titles-and-publications

About Vizgen®

Vizgen is at the forefront of spatial biology and multi-omics innovation. Through its pioneering MERFISH 2.0™ technology and MERSCOPE® Platform for in situ single-cell spatial genomics and its high-fidelity InSituPlex® protein assays and AI-driven STARVUE™ spatial image analysis technology, Vizgen delivers unmatched tools that enable researchers to uncover deep insights into human biology and achieve breakthroughs in understanding mechanisms of complex diseases, including neurodegenerative disorders and cancer. MERFISH and InSituPlex are for research use only. Vizgen is headquartered in Cambridge, Massachusetts, and can be found online at www.vizgen.com and www.ultivue.com. Connect on social media Twitter, LinkedIn and Facebook.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.